- Home
- GPOR vs NAMS Comparison
GPOR vs NAMS Comparison
Compare GPOR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPOR | NAMS |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.5B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | GPOR | NAMS |
|---|---|---|
| Price | $196.77 | $36.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $227.75 | $47.33 |
| AVG Volume (30 Days) | 247.3K | ★ 587.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.57 | N/A |
| Revenue | ★ $958,131,000.00 | N/A |
| Revenue This Year | $55.85 | $38.17 |
| Revenue Next Year | $7.83 | $573.62 |
| P/E Ratio | $13.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $153.41 | $14.06 |
| 52 Week High | $225.78 | $42.00 |
Technical Indicators
Market Signals| Indicator | GPOR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 59.27 |
| Support Level | $167.06 | $34.05 |
| Resistance Level | $214.82 | $37.26 |
| Average True Range (ATR) | 8.38 | 1.79 |
| MACD | -0.44 | 0.30 |
| Stochastic Oscillator | 23.17 | 71.78 |
Price Performance
Historical ComparisonAbout GPOR Gulfport Energy Corporation
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.